[ad_1]
Bristol-Myers Squibb (BMY), which is trying to convince its shareholders to support the $ 74-billion Celgene acquisition project (CELG), could scuttle its project by two highly influential financial advisers.
ISS and Glass Lewis, two global companies that make recommendations to institutional investors, have not yet considered the potential merger. Together, they claim a shareholder market share of about 97% and their verdict on the deal could spoil the largest pharmaceutical acquisition in history.
What is it?
STAT Plus is a premium subscription that offers scalable biopharmaceutical market coverage and in-depth scientific reports from a team with several decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and first examination of advanced laboratories and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Monthly live subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link